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Abstract
Facioscapulohumeral muscular dystrophy is caused by incomplete repression of the transcription factor DUX4 in skeletal
muscle as a consequence of D4Z4 macrosatellite repeat contraction in chromosome 4q35 (FSHD1) or variants in genes
encoding D4Z4 chromatin repressors (FSHD2). A clinical hallmark of FSHD is variability in onset and progression
suggesting the presence of disease modifiers. A well-known cis modifier is the polymorphic DUX4 polyadenylation signal
(PAS) that defines FSHD permissive alleles: D4Z4 chromatin relaxation on non-permissive alleles which lack the DUX4-
PAS cannot cause disease in the absence of stable DUX4 mRNA. We have explored the nature and relevance of a common
variant of the major FSHD haplotype 4A161, which is defined by 1.6 kb size difference of the most distal D4Z4 repeat unit.
While the short variant (4A161S) has been extensively studied, we demonstrate that the long variant (4A161L) is relatively
common in the European population, is capable of expressing DUX4, but that DUX4 mRNA processing differs from
4A161S. While we do not find evidence for a difference in disease severity between FSHD carriers of an 4A161S or 4A161L
allele, our study does uncover biallelic DUX4 expression in FSHD2 patients. Compared to control individuals, we observed
an increased frequency of FSHD2 patients homozygous for disease permissive alleles, and who are thus capable of biallelic
DUX4 expression, while SMCHD1 variant carriers with only one permissive allele were significantly more often
asymptomatic. This suggests that biallelic DUX4 expression lowers the threshold for disease presentation and is a modifier
for disease severity in FSHD2.
Introduction
Facioscapulohumeral dystrophy (FSHD; OMIM 158900 &
158901) is one of the more common hereditary myopathies
characterized by a descending pattern of muscle weakness
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starting in the face and progressing into the upper extremity
muscles. The disease typically starts in the second decade of
life and often the pattern of muscle involvement is asym-
metric. With disease progression, also other muscles may
become involved. Despite the well recognizable core phe-
notype, the clinical hallmark of the disease is the large
variability in onset and progression, both between and
within families. While approximately one fifth of gene
carriers will become wheelchair-dependent, an equal pro-
portion of gene carriers will remain asymptomatic or
minimally affected throughout life (reviewed in [1]).
FSHD is caused by incomplete repression of the DUX4
retrogene (OMIM 606009) in skeletal muscle [2–6]. DUX4
is a transcription factor normally expressed in the luminal
cells of the testis and in cleavage stage embryos but
repressed in somatic tissue such as skeletal muscle [7–10].
Incomplete repression, as observed in FSHD muscle, leads
to the activation and de-activation of a complex pattern of
transcriptional pathways eventually leading to muscle cell
death [11–15]. A copy of the DUX4 retrogene is embedded
within each unit of the D4Z4 macrosatellite repeat array on
chromosome 4, which is polymorphic in repeat number and
normally varies between 8–100 copies [3, 4, 16, 17]. Either
by contraction to a size of 1–10 units (FSHD1), or by
monoallelic variants in genes encoding somatic D4Z4
chromatin repressors such as SMCHD1 and DNMT3B
(FSHD2), somatic repression of DUX4 is incomplete lead-
ing to presence of DUX4 protein in a proportion of myo-
nuclei [18–20]. Consequently, a prominent difference
between FSHD1 and FSHD2 is that while in FSHD1 the
D4Z4 chromatin changes are restricted to the contracted
































Fig. 1 a Graphical
representation of the D4Z4 locus
on 4A161S and 4A161L alleles.
The 4A161 variants vary in size
by 1.6 kb in the most distal and
partial D4Z4 unit, which is
followed by identical pLAM
sequences encompassing the
DUX4 polyadenylation signal.
The size of the complete D4Z4
unit preceding the most distal
partial unit is identical between
both variants and all other D4Z4
haplotypes. The length variation
of D4Z4 repeat arrays is
determined by variability in the
number of 3.3 kb internal D4Z4
units (n). The DUX4 gene
structure including exons 1–3
and the open reading frame
(ORF) is indicated, as well as
the D4Z4 and pLAM region and
the intron-intron composition in
the 4A161S allele. The primers
that are used for the genotyping
PCR (4A161S and 4A161L) in
Fig. 2 are also indicated. b
Immunofluorescence staining of
myotubes derived from FSHD1
and FSHD2 patients. The size in
units (U) and haplotype
background of both D4Z4 repeat
arrays on chromosome 4 is
indicated and the pathogenic
alleles are underlined. DUX4
protein is expressed from both
4A161S (2402 and 2332) and
4A161L (2332 and 2440)
alleles. DAPI staining in blue,
myosin in red and DUX4 in
green. Scale bar is indicated
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observed on the D4Z4 arrays of both chromosomes 4, and
on the highly homologous D4Z4 arrays on chromosome 10
[21, 22]. We and others have reported overlap in repeat
sizes between controls and FSHD1 in the range of 8–10
units [16, 23]. This size range is marked by high clinical
variability in disease onset, with affected individuals often
showing more D4Z4 hypomethylation at their FSHD allele
than asymptomatic family members carrying the same dis-
ease allele [24–26]. We also identified FSHD2 patients
(thus having a variant in SMCHD1 or DNMT3B) who also
carry a permissive allele with 8–10 D4Z4 units [19, 27].
These patients typically show an earlier disease onset and
more rapid progression in comparison to their family
members carrying the D4Z4 disease allele without the
FSHD2 variant suggesting that both disease genes can also
act as modifier genes in FSHD1.
The DUX4 retrogene within the D4Z4 unit lacks a sta-
bilizing polyadenylation signal (PAS) but can make use of
an additional exon immediately distal to the repeat that
contains a stabilizing DUX4 PAS [2]. The DUX4-PAS is
polymorphic in nature and this explains the chromosome-
and haplotype-specificity of FSHD: a DUX4-PAS is present
on 4qA chromosomes but absent from 4qB chromosomes
and from chromosome 10 [5, 28]. Hence, FSHD patients
have at least one 4qA chromosome from which DUX4 can
be expressed in muscle, either because of repeat array con-
traction, or because of a variant in SMCHD1 or DNMT3B.
The 4qA and 4qB haplotypes can be divided in several
subgroups based on a simple sequence length polymorph-
ism (SSLP) proximal to the repeat (Fig. S1) [16, 29]. The
sequence of the most distal D4Z4 unit immediately prox-
imal to the pLAM sequence is virtually identical for almost
all 4qA haplotypes [5]. The exception to this is the most
common haplotype 4A161, accounting for 85% of FSHD
patients and defined by an SSLP length of 161 nucleotides
and the distal 4qA variant. Earlier studies have shown that
the 4A161 haplotype can end in two genetically distinct
variants, 4qA and 4qA-L (long), which diverge by a 1.6 kb
size difference of the most distal partial D4Z4 unit, fol-
lowed by identical pLAM sequences in which the DUX4-
PAS is located (Fig. 1a and Fig. S1) [17].
Although it has been described that D4Z4 repeat con-
traction results in FSHD1 from the 4A161 haplotype with
the canonical 4qA distal end (hereafter called 4A161S) and
with an extended 4qA-L distal end (hereafter called
4A161L) [5], the relative frequency and repeat size dis-
tribution of 4A161S and 4A161L and the identity of the
DUX4 transcript from the 4A161L haplotype is currently
unknown. In this study we determined the frequency and
distribution of the two 4A161 haplotypes in the control and
FSHD1 and FSHD2 patient population, determined the
nature of the DUX4 transcripts from the 4A161L allele, and
explored potential clinical consequences.
Results
DUX4 expression in FSHD1 and FSHD2 myotubes with
either a 4A161S or 4A161L pathogenic allele
Based on protein prediction, 4A161S and 4A161L alleles
both contain an identical DUX4 open reading frame (ORF)
of 424 amino acids since exon 1, which contains the entire
ORF, is not affected by the distal variation (Fig. 1a). Pre-
viously, we showed that FSHD1 is caused by contracted
D4Z4 repeats on both 4A161S and 4A161L alleles [5].
Here, we performed immunofluorescence analysis on
myotube cultures derived from FSHD1 and FSHD2
patients, in which the pathogenic repeat is either on a
4A161S or 4A161L background. As shown in representa-
tive immunofluorescence images in Fig. 1b, a comparable
pattern of DUX4 positive nuclei can be detected in all
situations suggesting that DUX4 expression is possible
from both 4A161 variants and that both variants indeed
encode a DUX4 protein that can be detected with the same
antibody.
4A161L haplotype is enriched in the European
population
To gain insight into the frequency of the 4A161S and
4A161L haplotypes in different populations, we developed
4A161S and 4A161L-specific primer pairs (Fig. 1a) and
analysed independent HAPMAP samples from the Nigerian
(Yoruban-YRI, n= 60; totalling 30 independent 4A161
alleles), Caucasian (CEU, n= 58; 50 independent 4A161
alleles), Japanese (JPT, n= 44; 31 independent 4A161
alleles), and Han Chinese (CHB, n= 45; 30 independent
4A161 alleles) panels for the presence of both variants.
Detailed D4Z4 genotyping, including repeat sizing and
haplotype analysis, of these panels was already performed
in a previous study [29]. The specificity of the primer pairs
is shown in Fig. 2a, demonstrating that chromosome 10qA
alleles (carrying a 4A161S-like distal end, but with specific
sequence variants) and 4qB alleles are not being amplified.
Based on available HAPMAP samples carrying one or two
4A161 alleles, we found that the 4A161L haplotype is
absent in the African and Asian samples from the HAPMAP
panels and can be found at a frequency of 17.0% (8/47)
in the Caucasian (of European origin) HAPMAP samples
(Fig. 2b).
For sixteen 4A161S, eleven 4A161L and 32 other 4qA,
4qB, and 10q haplotypes we cloned and sequenced the
distal variable region from independent individuals
according to our previous study [5], and confirmed that
independent alleles of the same haplotype have identical
sequences (Table S1). We did not find the 4qA-L extension
in combination with other 4qter haplotypes, as expected
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from the evolution of D4Z4 haplotypes [29]. We expanded
the control group (not linked to FSHD) with samples col-
lected in our lab to 667 independent Caucasian samples:
370 from the Netherlands and 297 with non-Dutch Cauca-
sian background. We identified 517 4A161 alleles out of a
total of 1334 4q alleles (39,4%), for which we further
determined the distal variation in 313 samples. We observed
slightly more 4A161L alleles in the Dutch cohort compared
to non-Dutch Caucasian cohort and the CEU HAPMAP
samples, but this difference is not significant (p= 0.199).
Upon merging all Caucasian samples, we identified 89
(24.7%) 4A161L and 271 (75.3%) 4A161S alleles (Fig. 2b).
Upper-sized FSHD alleles have a different 4A161S and
4A161L distribution
We next studied the frequency of 4A161S and 4A161L in
the Caucasian FSHD population. We analysed 720 FSHD1
patients and 49 unaffected carriers from 432 families and
identified a 4A161 FSHD allele in 411 families (95.4%).
The other FSHD1 families carried an FSHD allele of a rarer
haplotype (4A157, 4A159, 4A168, 4A166H, or D4F104S1
deletion). For 315 families with a 4A161 FSHD allele we
determined the distal variation of the disease allele and
identified 251 4A161S and 65 4A161L (20.6%) alleles.
Within the FSHD1 cohort, we identified 39 mosaic FSHD1
patients with a de novo contraction of D4Z4 and for them
we found comparable ratios (33.3% 4A161L), suggesting
that both 4A161 variants are equally recombinogenic (Table
S2). We then binned the 4A161S and 4A161L FSHD1
alleles, according to the D4Z4 repeat array size. For FSHD1
alleles with a D4Z4 array between 1–7 units, we found
ratios between 4A161S and 4A161L comparable to the ratio
in the Caucasian control population. However, we found a
significantly (p= 8.18e–05) smaller number of FSHD1
patients with an array of 8–10 D4Z4 repeat units on a
4A161L allele (Fig. 3). We also analyzed the FSHD allele
in 14 Asian FSHD1 patients and found thirteen 4A161S
alleles and one hybrid 4A166H allele, like in the Asian
HAPMAP populations (results not shown).
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a bFig. 2 4A161S and 4A161L
PCR and frequency of 4A161
haplotypes in different
populations. a Genotyping PCR
for the discrimination between
4A161S (286 bp) and 4A161L
(330 bp) alleles. Samples 1 and
2 carry a 4A161S (S) and
4A161L (L) allele, samples 3
and 4 carry one 4A161S and one
4qB allele and sample 5 carries
one 4A161L and one 4qB allele.
The position of the primers and
the amplicon size are shown in
Fig. 1a. b Bar diagram showing
the distribution of 4A161S and
4A161L alleles in three
HAPMAP populations and two
in-house control populations.
The in-house populations were
divided in European (without
























































































Fig. 3 Bar diagram showing the distribution of 4A161S and 4A161L
alleles in the European controls and FSHD1 patients (non-mosaic and
mosaic patients). Only unique control and FSHD1 alleles are included.
After binning of 4A161S and 4A161L FSHD1 alleles into 1-7U and 8-
10U bins, we observed a significant paucity (p= 8.18e-05) of 8–10
D4Z4 repeat units on a 4A161L allele. On the right site of the graph
results are shown for binning to individual D4Z4 repeat array sizes
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To explain the lack of 4A161L alleles with 8–10 D4Z4
repeat units in the FSHD1 cohort, we analysed the D4Z4
array size distribution for 4A161S and 4A161L alleles (n=
360) in the European controls in more detail. Like in the
FSHD1 cohort, in controls we found a paucity of 4A161L
alleles with 8–10 D4Z4 repeat units and found that this
4A161L paucity extends to repeat sizes of 14 units. The
number of 4A161L alleles (n= 1) with array size between 8
4A161L (2440)
4A161S (2315)
LLL S+L S+L S+L
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and 14 units in controls is significantly smaller (p-value=
0.0109) compared to the number of 4A161S alleles (n= 28)
(Figure S2a and S2b). We also determined the allelic var-
iation of 4A161 alleles in FSHD2 patients. We studied 79
FSHD2 families based on D4Z4 hypomethylation and the
presence of an SMCHD1 variant totalling 137 affected and
unaffected SMCHD1 variant carriers. We determined the
allelic variation of 4A161 alleles in 72 affected individuals
with an ACSS ≥ 50 or in probands with a clear
FSHD phenotype but without documented ACSS. We
found an increased frequency of 4A161 alleles with
D4Z4 repeat arrays ≤ 14 units in FSHD2 patients, but we
did not find a significant paucity of 4A161L alleles in this
group compared to >15 units repeat arrays (p= 0.301,
(Fig. S2c)).
Methylation analysis of 4A161S and 4A161L alleles
D4Z4 has a high GC content (73%) and displays high CpG
methylation in somatic cells of control individuals. In
FSHD, D4Z4 methylation is reduced. Moreover, CpG
methylation analysis of the FseI restriction site in D4Z4 has
shown D4Z4 repeat size-dependent methylation in controls,
and in FSHD1 and FSHD2 individuals. Consequently, in
general the shortest D4Z4 repeat sizes have the lowest CpG
methylation. Based on the correlation between repeat size
and methylation we were able to consistently predict the
methylation of D4Z4 given the repeat sizes. The predicted
methylation value was almost identical to the observed
methylation in controls and FSHD1 patients that carried a
D4Z4 repeat between 1–6 units [26]. However, in FSHD1
patients carrying a D4Z4 repeat between 7–10 units we
found that the observed methylation is significantly lower
than the predicted methylation, as expressed in the Delta1
value. This suggests that for repeat sizes between 7–10 units
an additional reduction in CpG methylation contributes to
pathogenic chromatin relaxation associated with somatic
DUX4 expression. We confirmed the significant reduced
Delta1 value for FSHD1 patients with arrays of 7–10 D4Z4
units in this study (1–6 unit, mean –0.8%; 7–10 unit, mean
−4,6%; p= 0.0002) (Fig. S3).
A recent bisulfite sequencing methylation analysis stu-
died the methylation of the pLAM region distal to D4Z4
without discriminating between 4A161S and 4A161L [30].
Re-analysis of the most informative CpG from this study
(CpG6) showed that D4Z4 repeat size-dependent methyla-
tion can be observed in both 4A161S and 4A161L alleles
and that the methylation values for both 4qA variants are
comparable at identical repeat sizes (Fig. S4).
Transcript analysis
Based on the DNA sequence, we expected that 4A161L and
4A161S alleles possibly encode for an identical DUX4
transcript, where the distal D4Z4 extension would represent
an extended DUX4 intron 2. However, RT-PCR analysis
using RNA from myotube cultures of FSHD1 patients with
a contraction on a 4A161L allele using previously described
4A161S transcript-based primers [5] failed to yield a pro-
duct. As the reverse PCR primer of this primer pair strad-
dles exons 2 and 3 of the 4A161S DUX4 transcript, the RT-
PCR failure on 4A161L RNA suggested a different DUX4
intron–exon structure.
To gain more insight in the transcript from 4A161L
alleles we aligned DUX4 4A161S and 4A161L RNAseq
reads from a previous study [13] to the reference genome of
chromosome 4. The standard HG19 and HG38 reference
genomes do not contain a 4A161 sequence, but the 4qB
refseq sequence from hg19 suggested that a portion of the
extended D4Z4 region in patients with a pathogenic
4A161L allele is transcribed rather than being intronic (Fig.
4a). Therefore, we aligned the 4A161L RNAseq reads in the
integrative genomics viewer (IGV) to the 4A161L reference
sequence available in HG38 Patch 7 (KQ983258.1). The
new alignment suggested the presence of a DUX4 transcript
with an exon 3 that is proximally extended compared to the
DUX4 transcript from 4A161S alleles (Fig. 4b, alignment in
IGV). Based on the IGV alignment RT-PCR primers were
designed, which identified the presence of two alternative
4A161L transcripts, which we named DUX4La and
DUX4Lb, where the longest and most prevalent isoform is
DUX4La (Fig. 4b). The amplification of 4A161L is
Fig. 4 a Representative RNAseq coverage tracks in the UCSC genome browser of differentiated myoblast obtained from FSHD patients
expressing DUX4 from a 4A161S, or from a 4A161L allele. The reads are aligned to the 4qB-type D4Z4 locus of reference genome GRCh37
(hg19), as the 4qA sequences are not standard available in GRCh37 and GRCh38. The indicated region includes three D4Z4 units depicted on top
of the UCSC track. The boxed region (red) shows the extra reads that are specific for the DUX4 transcript from 4A161L allele. b IGV alignment of
DUX4 reads from 4A161L allele aligned to 4A161L allele available in GRCh38.p7 (KQ983258.1). The 4A161L sequence shown covers a
complete internal D4Z4 unit, the most distal partial D4Z4 unit and the pLAM region distal to D4Z4. Forward reads are shown in pink and reverse
reads in purple. The exons 1 and 2 region that is similar between 4A161S and 4A161L DUX4 transcripts is shown. The 4A161L-specific exons 3a
and exon 3b region is boxed and shows several specific reads, the 4A161S-specific exon 3 region is shown with a dotted box (E3). An overview of
the two major DUX4 transcripts (DUX4La and DUX4Lb) produced from a derepressed 4A161L allele is shown below with uninterrupted lines
representing exons and interrupted lines representing introns. The primers and amplicons that were used for the identification of the 4A161L
transcripts are indicated. The position of the KpnI restriction site, DUX4 transcriptional and translation start sites (TSS and ATG) and poly-
adenylation signal (PAS) are indicated as well as the intron-exon composition for DUX4La and DUX4Lb
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hampered by the high GC-content in D4Z4 and specifically
the high Cytosine content (70%) in the region 599–737 bp
proximal to the DUX4 polyadenylation signal. These pro-
blems are encountered for PCR and Sanger sequencing of
DNA and RNA, and also for 3′ RACE reaction. The iden-
tified 4A161L DUX4 transcripts have been submitted to
Genbank under accession numbers MF422078 (DUX4La)
and MF422079 (DUX4Lb). 4A161L sequences with intron-
exon structure and exon numbering of the DUX4La and
DUX4Lb transcript can be found in Genbank under
accession numbers MF693913 and KQ983258.1 (Supple-
mentary Table 1). The gene features of Genbank accession
number MF693913 are depicted in detail in
Fig. S5.
Pathogenicity 4A161S and 4A161L alleles in FSHD1
We analyzed the correlation between clinical severity and
repeat array size in FSHD1 patients carrying a 4A161S or
4A161L FSHD allele. For this we focussed on FSHD1
alleles that range between 1–7 D4Z4 units, because of the
4A161L paucity in the 8–10 D4Z4 units size range. We
selected one patient per family of at least 25 years of age
and excluded mosaic FSHD1 patients, and used the age
corrected clinical severity score (ACSS) [31, 32]. We did
not find a significant difference (p= 0.0611) in clinical
severity between carriers of a 4A161S or a 4A161L FSHD
allele (Fig. S6).
Expression from two permissive alleles in FSHD2
The severity of FSHD2 is in part determined by the size of
the permissive allele and in part by the nature of the
SMCHD1 variant [26]. In most FSHD2 cases the size of the
pathogenic 4qA allele ranges between 8 and 20 units, while
SMCHD1 variant carriers with 4qA alleles > 20 units often
remain asymptomatic. Some FSHD2 patients carry two
permissive alleles and in these cases we expect that DUX4
is exclusively expressed from the shortest array in patient
derived myotubes, if the second allele contains >20 D4Z4
units. To study this we used the RT-PCR primers specific
for either 4A161S or 4A161L-derived DUX4 transcripts in
an endpoint PCR and analyzed myotube cultures obtained
from FSHD2 patients carrying a 4A161S and a 4A161L
permissive allele (Fig. 5). Negative control myotube cul-
tures were from unaffected controls carrying normal-sized
D4Z4 arrays on a 4A161S or 4A161L allele and PCR-
specificity was confirmed on myotube cultures from FSHD1
patients carrying a D4Z4 repeat array contraction on either a
4A161S or a 4A161L FSHD allele. Surprisingly, in 3 out of
4 FSHD2 myotube cultures we observed expression from
both the 4A161S as from the 4A161L allele, probably as a
consequence of the overall D4Z4 derepression. Although
these are non-quantitative RT-PCR experiments, the signal
intensities of the RT-PCR products suggest that in all cases
DUX4 expression levels are highest from the allele with the
shortest D4Z4 repeat array.
This finding suggests that the presence of two permissive
4qA alleles might increase DUX4 expression levels as a
consequence of bi-allelic expression and may result in a
more severe phenotype in some FSHD2 cases. This could
cause an excess of FSHD2 individuals carrying two per-
missive alleles because of increased penetrance. To address
this issue, we determined the haplotype of the second D4Z4
allele in FSHD2 patients and control individuals carrying a
permissive allele with ≤30 D4Z4 units. As shown in Table
1, 38 FSHD2 patients (40.9%) carried one permissive allele,
while 55 (59.1%) carried two permissive alleles. In controls
this ratio was 151 (60.9%) against 97 (39.1%), which is a
significant difference (p= 0.00142). This suggests that
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Fig. 5 Endpoint 4A161S- and 4A161L-specific RT-PCR on differ-
entiated myoblasts obtained from controls and FSHD patients. For
both chromosomes 4 (4q1 and 4q2) the haplotype is indicated
(4A161S [S], 4A161L [L] or 4qB [B]) and the repeat size is shown
between parenthesis. The specificity of the 4A161S and 4A161L pri-
mers is shown for the FSHD1 patients carrying a 4A161S or a 4A161L
FSHD allele (positive controls) and the control individuals (negative
controls). Three of the four FSHD2 patients show expression from
both the 4A161S and the 4A161L allele. Sequences of the products
were confirmed by Sanger sequencing
Table 1 Ratio between individuals that carry one (1xP) and two (2x)
permissive alleles in controls and FSHD2 patients carrying a
permissive allele with ≤30 D4Z4 units. Compared to control
individuals we find in FSHD2 patients a significant skewing
(p= 0.00142) of individuals carrying two permissive alleles. This
difference is significant (p= 0.00142) when the shortest permissive
allele is 30 units or smaller
1xP 2xP
Control 151 (60,9%) 97 (39.1%)
FSHD2 38 (40.9%) 55 (59.1%)
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To further study the clinical consequences of having a
second permissive allele, we compared the ACSS in FSHD2
patients of 30 years and older [33] carrying one or two
permissive alleles. Despite the biallelic expression of DUX4
in muscle cell cultures of FSHD2 individuals with two
permissive alleles, we did not observe a significant differ-
ence (p= 0.126) in clinical severity between individuals
carrying one or two permissive 4qA alleles (Fig. 6a).
Interestingly, we observe an opposite ratio of one permis-
sive allele (1xP) vs. two permissive alleles (2xP) between
affected SMCHD1 variant carriers (1xP:2xP= 25:35) and
unaffected or mildly affected carriers (1xP:2xP= 10:3).
This difference is significant (p= 0.0454) and suggests that
for FSHD2 the number of permissive alleles may code-
termine the likelihood of developing FSHD (Fig. 6b).
Discussion
FSHD is clinically characterized by substantial variability in
onset and progression of the disease, even within FSHD1
families where individuals at risk carry the same D4Z4
repeat array contraction [34–36]. This suggests that modi-
fiers increase the risk of developing FSHD and determine
the progression of the disease. The existence of such
modifiers is supported by different lines of evidence. For
example, while the diagnostic cut-off for FSHD1 has been
defined as maximally 10 D4Z4 repeat units, 1–3% of the
European population carries a D4Z4 repeat array of 8–10
units on a FSHD-permissive haplotype [16, 23]. In addition,
while variants in the genes encoding the chromatin repres-
sors SMCHD1 and DNMT3B have been shown to cause
FSHD2 when combined with an intermediate-sized D4Z4
repeat array (11–20 units) on a FSHD permissive chromo-
some 4, variants in the same genes have also shown to act as
modifier genes for disease severity in some FSHD1 families
that carry a permissive D4Z4 repeat array of 8–10 units
[18, 19, 27, 37]. Therefore, it is plausible that additional cis
(i.e. variants in 4qter) and trans (i.e., variants in D4Z4
chromatin factors) modifiers exist that influence FSHD
disease penetrance and progression, in addition to other
factors such as perhaps DUX4 pathway modifiers.
Perhaps the most influential cis modifier is the DUX4-
PAS variant, which is essential for the stabilization of the
DUX4 transcript in muscle cells [5]. Consequently, D4Z4
repeat array contractions on chromosomes that lack the
DUX4-PAS, such as 4B chromosomes, do not result in the
production of DUX4 protein and disease presentation.
Moreover, additional polymorphic sequences immediately
downstream of the DUX4-PAS were recently identified that
are critical for DUX4 cleavage and polyadenylation [38]. In
this study we molecularly characterized and studied the
clinical consequence of another major variation in the most
common FSHD permissive haplotype 4A161. Previous
studies had already demonstrated that the partial most distal
D4Z4 repeat unit can differ in size in patients and controls,
either being 0.3 kb (4A161S) or 1.9 kb (4A161L) long
[5, 17], but the frequency and distribution of both variants
over the different haplotypes was unknown. Moreover,
while the DUX4 locus in the 4A161S allele has been
extensively studied, the 4A161L has not been studied in this
respect.
Our population studies indicate that the 4A161L variant
is a rather recent modification of the 4A161S allele that is
relatively common in the European population but absent,
or very uncommon in the Asian and African populations.
This is consistent with our previous study into the evolu-
tionary network of 4qter, in which we predicted 4A161S
and 4A161L to be closely related [29]. RNA and protein
studies showed that both variants can produce stable DUX4
transcripts in muscle cell cultures, that both variants display
a similar repeat size dependent methylation pattern, and that
there is no evidence that either variant affects function more
than the other based on the ACSS. Both variants, however,
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1xP (n=35) 2xP (n=38)
ACSS≥50 25 35
ACSS <50 10 3
P=0.0454
SMCHD1 muta on carriers (>29 years)
Fig. 6 a Scatter plot showing the ACSS for SMCHD1 variant carriers
that carry one (1xP, red dots) or two (2xP, blue dots) permissive
alleles. All carriers were 30 years or older. The X-axis shows the log2
value of the D4Z4 repeat size of shortest permissive allele. For both
situations we find that the disease severity drops by the size of the
repeat (p= 0.0008). We did not find a significant difference in the
severity between carriers of one or two permissive alleles. Regression
lines are shown in blue (2xP) and red (1xP). b We found significantly
more unaffected or mildly affected (ACSS< 50) carriers with only one
permissive allele (p= 0.454)
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4A161L uses two alternative 3′ splice sites that are not
present on the 4A161S allele. As a consequence two
alternative DUX4 transcripts can be produced from 4A161L
alleles, DUX4La and DUX4Lb, that carry a 5′ extended
exon 3 compared to the DUX4 transcript from 4A161S
alleles.
A noteworthy observation is that some FSHD2 patients
can express DUX4 from both alleles. Biallelic DUX4
expression is surprising since earlier studies have shown
that intermediate-sized D4Z4 alleles ranging from 11–20
units are particularly sensitive to the consequences of het-
erozygous SMCHD1 variants, while only few FSHD2
patients carry a permissive allele that exceed 20 units [26].
Perhaps other mechanisms are at play in these patients
which make both alleles susceptible to DUX4 expression.
We did not find evidence that biallelic DUX4 expression
leads to a more severe disease presentation. Rather, our
study in the FSHD2 population does suggest that the pre-
sence of two permissive alleles, and therefore being at risk
for biallelic DUX4 expression, increases the penetrance of
FSHD. This suggests that the threshold for DUX4 expres-
sion in vivo is higher in FSHD2 individuals consistent with
the relatively milder disease presentation in FSHD2 [33].
Another surprising observation is the significant lack of
4A161L alleles with D4Z4 repeat sizes of 8–10 units in the
FSHD1 population, but not in the 1–7 units range. This may
suggest that 4A161L alleles are less susceptible to DUX4
expression and FSHD than 4A161S alleles in this size
range. However, we did not find a difference in the ACSS
between FSHD1 patients carrying either a 4A161S or a
4A161L allele with 1–7 D4Z4 units. We also did not find a
difference between the frequency of 4A161S and 4A161L
alleles for de novo mosaic D4Z4 contractions leading to
FSHD1, suggesting that both haplotypes are equally
recombinogenic. Our population studies, however, revealed
10.3% 4A161S alleles with repeat sizes of 8–14 D4Z4 units
and only 1.1% 4A161L alleles with this size range. This
parallel between controls and FSHD1 therefore suggests
that in this size range there is no selection pressure but it is
rather a consequence of the recent evolutionary origin of
this haplotype.
FSHD2 patients show a different size distribution of
permissive (mostly 4A161) alleles. While in controls 8–14
units compared to >14 unit repeat sizes on 4A161S and
4A161L alleles are less common to rare, they are very
common in FSHD2 patients (Figure S2) as this size range is
highly sensitive to D4Z4 chromatin relaxation and DUX4
derepression as a consequence of SMCHD1 variants [26].
Strikingly, for unknown reasons, we do not observe the
paucity of 8–14 units 4A161L alleles in FSHD2 patients.
Previously, we and others recognized a difference in the
predictive value of a genetic diagnosis for FSHD1, where
1–7 D4Z4 unit arrays typically result in an FSHD
phenotype, while the clinical consequences of arrays 8–10
units are highly unpredictable and can also be found in the
control population [16, 23]. Recently, several groups
showed that for carriers of 7–10 unit D4Z4 repeat the
degree of CpG methylation to some extent correlates with
disease penetrance [24–27]. Apparently, in this size range,
FSHD mostly develops in a complex fashion with addi-
tional requirement factors that further reduce the methyla-
tion of D4Z4 beyond that what can be expected from the
contraction itself. The current finding of a shortage of
4A161L compared to 4A161S alleles in the 8–10 units size
range, corroborates this finding. D4Z4 array sizes between
8–10 units on 4A161S alleles can be found in 1–3% of the
control population and in combination with D4Z4 hypo-
methylation result in FSHD. However, on 4A161L alleles
these repeat sizes are extremely rare and therefore will
unlikely appear in the hypomethylation dependent 8–10 unit
FSHD population, because of the digenic nature.
Overall, recent developments in our understanding of the
genetic and epigenetic factors that govern DUX4 repression
in skeletal muscle may ask for a revision of the definition of
FSHD1 and FSHD2. We propose that FSHD1 and FSHD2
belong to the same disease continuum in which FSHD1
represents a spectrum of the disease caused by D4Z4 con-
tractions on a permissive D4Z4 array to relatively short
D4Z4 repeat sizes (1–7U) with limited additive effect of
variation in epigenetic modifiers of the D4Z4 chromatin
structure. FSHD2 is typically more often found in indivi-
duals with longer D4Z4 array sizes (8–20U) in combination
with the contribution of additional factors that determine the
likelihood of DUX4 expression in skeletal muscle, such as
genetic variants that influence the activity or levels of the
D4Z4 chromatin repressors SMCHD1 and DNMT3B.
Materials and methods
Subjects
This study was approved by the relevant Medical Ethical
Committees from participating institutions. For controls, we
analyzed HAPMAP samples from the Nigerian (Yoruban-
YRI, n= 60), Caucasian (CEU, n= 58), Japanese (JPT, n
= 44) and Han Chinese (CHB, n= 45) panels. The Cau-
casian control (not linked to FSHD) samples were expanded
with 667 independent Caucasian samples collected at the
LUMC, 370 from the Netherlands and 297 with other
European background. For FSHD1, we analyzed 720
patients and 48 unaffected carriers (family members from
FSHD1 patients) from 431 families. Thirty-nine of the 720
patients carried a mosaic FSHD allele. For FSHD2, we
analyzed 79 families with one or more FSHD2 patients. In
total we studied 139 carriers of an SMCHD1 variant, of
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which 110 were affected and 29 unaffected. Eleven of these
29 unaffected cases carried two non-permissive alleles. For
most individuals the D4Z4 repeat sizes and haplotypes have
been described previously [26, 29]. Clinical evaluation was
performed by an experienced neurologist after informed
consent. For the clinical severity we used the age corrected
severity score (ACSS), based on the 10-scale Ricci score
[ACSS= (Ricci score/age at examination)× 1000] [31, 32].
The standardized clinical form is available at the website of
the Fields Center for FSHD Research (www.urmc.rochester.
edu/fieldscenter/).
Myoblasts
For immunofluorescence and DUX4 transcription analysis
we used 9 primary myoblast cell cultures. For all myoblasts
we analyzed the D4Z4 repeat sizes and haplotype as
described for blood. For the different experiments we used
two control lines (1926 and 2417), 4 FSHD1 lines (2326,
2358, 2402, and 2417) and 5 FSHD2 lines (1614, 2332,
2440, 2445, and 2453). Detailed genotype and methylation
information can be found in Table S3.
D4Z4 repeat sizing, haplotype analysis and methylation
analysis
All cohorts were analyzed for D4Z4 repeat size, genetic
background (haplotype) and CpG methylation at D4Z4.
Genomic DNA (gDNA) was isolated from PBMCs or from
lymphoblastoid cell lines for HAPMAP samples. The sizing
of the D4Z4 repeats was done by pulsed field gel electro-
phoresis, as described previously [26, 29]. Haplotypes were
determined by Southern blot hybridization of HindIII
digested genomic DNA with probes A and B in combina-
tion with PCR-based SSLP analysis according to previously
described protocols [29]. Methylation at the D4Z4 repeat
arrays was determined on blood-derived genomic DNA by
Southern blot and the methylation sensitive restriction
enzyme FseI, after which the delta1 value was calculated as
described previously [26]. Detailed protocols are freely
available from the Fields Center website (www.urmc.
rochester.edu/fields-center/).
Muscle cell culture and immunofluorescence staining
Human primary myoblast cell lines originated from the
University of Rochester bio repository. Primary myoblasts
were cultured in DMEM/F-10 media (#31550, Gibco/Life
Technologies, Bleiswijk, The Netherlands) supplemented
with 20% heat inactivated fetal bovine serum (FBS #10270,
Gibco/Life Technologies), 1% penicillin/streptomycin
(#15140, Gibco/Life Technologies), 10ng/ml rhFGF
(#G5071, Promega, Leiden, The Netherlands) and 1 μM
dexamethasone (#D2915, Sigma-Aldrich, Zwijndrecht, The
Netherlands). For differentiation the myoblasts were cul-
tured for 2–4 days in DMEM/F-12 Glutamax media
(#31331, Gibco/Life Technologies) containing 1% peni-
cillin and streptomycin and 2% KnockOut serum replace-
ment formulation (#10828, Gibco/Life Technologies).
Immunofluorescence staining on differentiated myoblasts
was performed as described previously [39]. The following
antibodies were used; E5-5 (1:100), primary rabbit-DUX4
antibody directed against the C-terminal region of human
DUX4 [40] with Alexa Fluor 488-conjugated donkey anti-
rabbit (1:400; Life Technologies) and MF-20 anti-myosin
(1∶100, Dako North America, Carpinteria CA, USA) with
Alexa-594-conjugated goat anti-mouse (1:400; Life Tech-
nologies). The cells were mounted on microscope slides
using Aqua Poly/Mount (PolySciences, Warrington PA,
U.S.A.) containing 500 ng/ml DAPI.
Determination of the distal variation at 4A161
D4Z4-pLAM sequences for 4A161S and 4A161L haplo-
types were obtained in individuals that carry one 4qA and
one 4qB chromosome. We used 4qA specific primers on
BlnI-digested genomic DNA to eliminate the 10qA chro-
mosomes and to specifically amplify the 4qA chromosome.
To amplify the 3.5 kb D4Z4-pLAM sequence of 4A161S
haplotype we used forward primer 9406LRF 5′-AGC GTT
CCA GGC GGG AGG GAA G-3′ and reverse primer PAS-
LRR 5‵-CAG GGG ATA TTG TGA CAT ATC TCT GCA
CTC ATC-3‵ and for 3.6 kb D4Z4-pLAM sequence of
4A161L haplotype we used the same reverse primer in
combination with forward primer 11007LRF 5′-AGC CCA
GGG TCC AGA TTT GGT TTC AG-3′ [5]. When indi-
viduals carried a 4A161S and 4A161L haplotype, we were
not able to generate a 3.5 kb 4A161L PCR fragment
because of preferential amplification of the shorter 4A161S
PCR fragment. In these cases, we generated a shorter 1.9 kb
4A161L PCR fragment using forward primer 9406LRF in
combination with reverse primer PAS-LRR. These PCR
reactions were performed on 125–140 ng of genomic DNA,
in a solution containing 3.5 µM each primer, 0.2 mM dATP,
0.4 mM dCTP, 0.2 mM dTTP, 0.2 mM dGTP and 0.2 mM
7-deaza-dGTP, 2.5 U of LA-Taq DNA polymerase and
supplemented with 2xGC buffer I (TAKARA), in a total
volume of 20 µl. The PCR conditions consisted of an initial
denaturation step at 94 °C for 5 min., followed by 34 cycles
of denaturation at 94 °C for 30 s, annealing at 68 °C for 30 s,
and extension at 72 °C for 3 min and 30 s. The final
extension time was 10 min. at 72 °C.
For genotyping of the distal variation (4A161S or
4A161L) of 4A161 alleles we developed 4A161S- and
4A161L-specific primer pairs and for both PCR reactions
we used 20 ng of genomic DNA in total a volume of 10 uL.
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For 4A161S amplicon (286 bp) we used forward primer
4AS-F 5′-CCC GCC CGG GCC CCT GCA-3′ and reverse
primer PAS-R 5‵-GAT CCA CAG GGA GGG GGC ATT
TTA-3‵. For the PCR reaction of 4A161S, final concentra-
tion are as follows: 1× Accuprime buffer II (Invitrogen),
10% DMSO, 0.25 μM each primer, 0.15 µl AccuPrime Taq
Polymerase. The PCR conditions consisted of an initial
denaturation step at 94 °C for 2 min. and 30 sec., followed a
touchdown PCR: 98 °C, 30 s; 73> 63 °C, 30 s and 68 °C,
30 s for 11 cycles, followed by 26 cycles at 94 °C, 30 s; 64 °
C, 30 s; 68 °C, 30 s. The final extension time was 10 min. at
72 °C. For the 4A161L amplicon (330 bp) we used forward
primer 4AL-F 5′-CGA GGA CGG CGA CGG AGA C -3′
in combination with reverse primer PAS-R. The final con-
centration of the 4A161L PCR are as follows: 1× buffer
Dreamtaq, 0.2 mM dNTPs, 0.25 μM each primer, 0.05 units
Dreamtaq Polymerase. The PCR conditions consisted of an
initial denaturation step at 95 °C for 5 min., followed by 35
cycles of denaturation at 95 °C for 10 s, annealing at 64 °C
for 20 s, and extension at 72 °C for 15 s. The final extension
time was 5 min. at 72 °C.
In silico alignment DUX4 reads
Reads were first analysed using FastQC (version 0.10.1). If
any known adapters were detected to be overrepresented by
FastQC, the full adapter sequence was then used for clip-
ping using the cutadapt tool (version 1.5), setting the
minimum read length to 20. In any case, low quality bases
in all reads were trimmed using the sickle tool (version
1.33) with default options. If cutadapt was performed before
running sickle, the paired reads are processed using a cus-
tom script beforehand to ensure the read pairs were still in-
sync. Mapping was done to the respective 4A161 allele
sequence using the GSNAP tool (version 2014-12-23) with
the following flags: –batch 4, –nthreads 8, –novelsplicing 1,
and –format sam. The resulting alignments were then
compressed, sorted, and indexed, before viewed in the IGV
tool.
Transcription analysis DUX4
Total RNA was extracted using the Qiagen RNAeasy iso-
lation kit with DnaseI treatment. The RNA concentration
was determined on a ND-1000 spectrophotometer (Thermo
Scientific, Wilmington, USA). cDNA was synthesized from
2 µg of total RNA using poly dT primers (Fermentas
RevertAid Transcripase kit). After 5 min at 70 °C, the
reverse transcription buffer was added, followed by 1 h
incubation at 42 °C, 10 min at 70 °C and put on ice. After
the reaction, cDNA was treated with RNAseH and 75 µL
water was added to an end volume of 100 µL.
For identification of the 4A161L transcript, we used
three overlapping amplicons. For the 5′ amplicon we used
forward primer 11007LRF 5′-AGC CCA GGG TCC AGA
TTT GGT TTC AG-3′ and reverse primer DUX4-STOP-R
5‵-CTA AAG CTC CTC CAG CAG AGC CCG GTA TTC-
3‵, for the central amplicon we used DUX4-STOP-F 5′-
GAA TAC CGG GCT CTG CTG GAG GAG CTT TAG-3′
and reverse primer 10589LRR 5‵-CGG AAG GGA CCC
AGG GCG TCG AG-3‵ and for the 3′ amplicon we used
10589 F 5′-CGC CCT GGG TCC CTT CCG-3′ and reverse
primer PAS-R 5‵-GAT CCA CAG GGA GGG GGC ATT
TTA-3‵. For all PCRs we used the following conditions in a
25 µl PCR reaction; input cDNA 2 µl cDNA, 1x Accuprime
buffer II (Invitrogen), supplemented with 0.2 mM 7-Deaza-
2‘-deoxyguanosine, 0.2 μM of each primer and 0,5 µl
AccuPrime Taq Polymerase. The PCR conditions consisted
of an initial denaturation step at 95 °C for 2 min., followed
by 40 cycles of denaturation at 94 °C for 30 s, annealing at
58 °C for 30 s, and extension at 68 °C for 2 min. 30 s. The
final extension time was 10 min. at 72 °C. All the primers
used were designed using Primer 3 software. To study bi-
allelic expression in FSHD2 we used the following PCR
conditions. For the 4A161S amplicon (164 bp) we used
forward primer DUX4RT-F2 5′- CCC AGG TAC CAG
CAG ACC-3′ and reverse primer pLAMR4 5‵- TCC AGG
AGA TGT AAC TCT AAT CCA-3‵. In a 15 µl PCR reac-
tion we used 5 microliter cDNA, 1× Sybrgreen PCR mix
(buffer and dNTP and Polymerase) and 0.33 μM of each
primer. The PCR conditions consisted of an initial dena-
turation step at 95 °C for 3 min., followed by 35 cycles of
denaturation at 95 °C for 10 s and annealing/extension for
30 s at 60 °C. For the 4A161L transcription analysis we
used the same conditions and amplicon (330 bp) as we used
to determine the 4A161L variation on DNA (primers 4AL-F
and PAS-R in a PCR volume of 15 uL with 5 uL cDNA).
Statistical analysis
To compare the ratio of 4A161S vs. 4A161L alleles
between the groups in Figs. 2, 3, 6 and Figure S2, we used a
Pearson chi-square test. Yates’ continuity correction was
used in chi-square tests in 2× 2 tables.
To model the relationship between the Delta1 value and
the repeat length in Figure S3, we fitted a linear mixed
model with Delta1 as the response and repeat length as a
fixed effect (dichotomized at a threshold of 7.5). The family
identifier was included as a random effect in the model.
For FSHD1 patients, severity was modeled as a function
of repeat size and 4A161S vs. 4A161L haplotype using a
linear mixed model with repeat length and haplotype and
their interaction as fixed effects, and with family identifier
as random effect. In this model we first tested for the pre-
sence of an interaction effect. Since the interaction was not
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significant, we left it out of the final model when testing
whether haplotype had a significant influence on severity,
assuming a common slope between haplotypes.
To test the effect of the number of permissive alleles on
the severity in FSHD2 patients a similar linear mixed model
was used, now containing the number of permissive alleles,
the logarithm of the length of the shortest permissive allele
and their interaction as fixed effects and family as random
effect. As above, we first tested the interaction effect, leaving
it out when it was found to be non-significant. The effect of
the number of permissive alleles was subsequently assessed
in a simpler model with common slope between groups.
All mixed models were fitted in R 3.3.2 [41] in the
MASS library [42] and Wald t-tests were used for assessing
significance.
Web Resources
The URLs for data presented herein are as follows:






DUX4 transcript accession numbers MF422078 (DUX4La)
and MF422079 (DUX4Lb) and for D4Z4 genomic acces-
sion numbers KQ983258.1, MF693913, MF503833,
MF503834, MF503835, MF503836, MF741677,
MF741678 (4A161L); MF776830, MF776831, MF776832,
MF776833, MF776834, MF776835 (4A161S); MF776826,
MF776827, MF776828, MF776829 (4A166) and
MF776824, MF776825 (4A166H1).
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